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Abstract
Pleural infection is a frequent clinical condition. Prompt treatment has been shown to reduce hospital costs, morbidity and mortality.
Recent advances in treatment have been variably implemented in clinical practice. This statement reviews the latest developments and con-
cepts to improve clinical management and stimulate further research. The European Association for Cardio-Thoracic Surgery (EACTS)
Thoracic Domain and the EACTS Pleural Diseases Working Group established a team of thoracic surgeons to produce a comprehensive
review of available scientiﬁc evidence with the aim to cover all aspects of surgical practice related to its treatment, in particular focusing on:
surgical treatment of empyema in adults; surgical treatment of empyema in children; and surgical treatment of post-pneumonectomy
empyema (PPE). In the management of Stage 1 empyema, prompt pleural space chest tube drainage is required. In patients with Stage 2 or
3 empyema who are ﬁt enough to undergo an operative procedure, there is a demonstrated beneﬁt of surgical debridement or decortica-
tion [possibly by video-assisted thoracoscopic surgery (VATS)] over tube thoracostomy alone in terms of treatment success and reduction in
hospital stay. In children, a primary operative approach is an effective management strategy, associated with a lower mortality rate and a re-
duction of tube thoracostomy duration, length of antibiotic therapy, reintervention rate and hospital stay. Intrapleural ﬁbrinolytic therapy is
a reasonable alternative to primary operative management. Uncomplicated PPE [without bronchopleural ﬁstula (BPF)] can be effectively
managed with minimally invasive techniques, including fenestration, pleural space irrigation and VATS debridement. PPE associated with
BPF can be effectively managed with individualized open surgical techniques, including direct repair, myoplastic and thoracoplastic techni-
ques. Intrathoracic vacuum-assisted closure may be considered as an adjunct to the standard treatment. The current literature cements the
role of VATS in the management of pleural empyema, even if the choice of surgical approach relies on the individual surgeon’s preference.
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INTRODUCTION
Pleural infection is a frequent clinical condition with an approxi-
mate annual incidence of 80 000 cases in the UK and USA com-
bined [1]. Of these, 20% may require surgical intervention, and
prompt treatment has been shown to reduce hospital costs, mor-
bidity and mortality [2]. The Pleural Disease Guideline Group of the
British Thoracic Society (BTS) published in 2010 a comprehensive
guideline document for the medical management of pleural in-
fection [3], with the aim to cover all aspects of surgical practice
related to the treatment of pleural empyema. It is the aim of the
European Association for Cardio-Thoracic Surgery (EACTS) to
assess the topics of pleural empyema focusing on surgical treat-
ment of empyema in adults and in children, and on surgical treat-
ment of post-pneumonectomy empyema (PPE).
METHODOLOGY
The EACTS Thoracic Domain and the Pleural Diseases Working
Group established a team of surgeons to produce a statement on
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the surgical treatment of pleural empyema. A statement is consid-
ered a comprehensive scientiﬁc review by a group of experts,
which is based on a body of scientiﬁc evidence identiﬁed by sys-
tematic searches and documented by references supporting the
conclusions. Initially, a set of key clinical questions was formulated
on the epidemiology, diagnosis and classiﬁcation of empyema,
and also on (i) surgical treatment of empyema in adults, (ii) surgi-
cal treatment of empyema in children and (iii) surgical treatment
of PPE. To obtain a body of scientiﬁc evidence, a systematic litera-
ture search was performed on medical databases Medline/
PUBMED (National Library of Medicine, USA), EMBASE (Elsevier,
Netherlands) and Cochrane Library (UK) [4, 5].
The initial search was performed in January 2013 and repeated
in September 2014. The search was limited to reference material
published since 1975 (Table 1).
Levels of evidence are derived from published papers (Table 2)
and recommendations classed by the strength of their recom-
mendation (Table 3).
The preliminary document was circulated among all the
involved members for further input and comments. A ﬁnal
version was then revised to incorporate all the pertinent com-
ments suggested and submitted to the EACTS Thoracic domain
and the Working Group on Pleural Diseases for further input and
implementation. The ﬁnal revised version of the document was
reviewed by the authors, ﬁnalized, approved and submitted to the
EACTS Thoracic Domain during the Annual Meeting in Milan,
Italy, 11–15 October 2014, for endorsement. After endorsement,
the paper was submitted to the Clinical Guidelines Committee for
formal evaluation and after ﬁnal approval submitted to the
European Journal of Cardio-Thoracic Surgery (EJCTS) for peer
review. This statement describes the current evidence and prac-
tices for pleural empyema.
It does not make recommendations for clinical practice.
DEFINITIONS OF PARAPNEUMONIC EFFUSION
AND EMPYEMA
The development of empyema in association with pneumonia is a
progressive process and has been classiﬁed [3] into three stages as
follows:
(1) Parapneumonic effusion (Stage 1), whereby the ﬂuid is a free-
ﬂowing exudate characterized by a low white cell count, an
LDH level less than half that in the serum, normal pH and
glucose levels and does not contain bacterial organisms.
(2) Fibrinopurulent stage (Stage 2), whereby there is bacterial inva-
sion across the damaged lung epithelium, and this stimulates
the immune response, creating ﬁbrin deposition and locula-
tions in the ﬂuid. At this stage, ﬂuid analysis may identify the
characteristic ﬁnding of a pH <7.20, glucose <2.2 mmol/l and
LDH over 1000 IU/l. Without pus, this may be termed a com-
plicated parapneumonic effusion, but if frank pus is found,
then this is most correctly called an empyema.
(3) Chronic organizing stage (Stage 3), with scar tissue (pleural
cortex) formation. In the later stages, a solid ﬁbrous pleural
cortex begins to form, which may encase the lung, preventing
re-expansion, impairing lung function and creating a persistent
pleural space with continuing potential for infection.
STAGING INVESTIGATIONS
A staging assessment, based mainly on the start of symptoms, is
not an easy task in some cases. Chest X-ray, ultrasound (US), and
computed tomographic (CT) scan are all required and considered
the mainstay imaging modalities for effusion [3]. The last decade
has seen a signiﬁcant trend worldwide to employ thoracic US at
the bedside to assess for the presence of effusions, especially in
the context of pleural infection.
Pleural ultrasound
Pleural US is fast, safe and effective in conﬁrming the presence of
pleural ﬂuid and estimating its volume, can differentiate between
Table 2: Level of evidence
Level A Data derived from multiple randomized clinical trials or
meta-analyses
Level B Data derived from a single randomized clinical trial or large
non-randomized trials
Level C Consensus of opinion of the experts and/or small studies,
retrospective studies, registries
Table 1: Methodology checklist
Yes No
Panel assembly
Experts from thoracic and cardiovascular surgery x
Experts vetted for conflict of interest x
Experts from Working Group on pleural diseases x
Experts from Clinical Guidelines Committee x
Literature review
Performed in collaboration with librarian x
Searched in multiple electronic databases (Medline/
PUBMED/EMBASE/Cochrane Library)
x
Reviewed reference list of retrieved articles x
Evidence synthesis
Pre-specified inclusion and exclusion criteria applied x
Evaluation of included studies for source of bias x
Explicitly summarized benefits and harms x
Grading system used x
Included studies evaluated
Recommendations for clinical practice x
Summary/opinions x
Table 3: Grade of recommendation
Class I Evidence and/or general agreement that a given treatment
or procedure is beneficial, useful, effective.
Class II Conflicting evidence and/or a divergence of opinion about
the usefulness/efficacy of the given treatment or
procedure.
Class IIa Weight of evidence/opinion is in favour of usefulness/
efficacy.
Class IIb Usefulness/efficacy is less well established by evidence/
opinion.
Class III Evidence or general agreement that the given treatment or
procedure is not useful/effective, and in some cases may
be harmful.
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pleural ﬂuid and thickening, and aids thoracocentesis in localizing
the optimal site for diagnostic and therapeutic intervention in real
time. The use of real-time pleural US by trained operators has
been shown to improve the safety of sampling effusions, with
reductions in iatrogenic pneumothoraces [3]. It has been currently
incorporated into diagnostic algorithms in major centres, it is sen-
sitive in detecting small volumes of ﬂuid and loculations often not
evident on CT, and is rapidly being considered as an extension of
the clinical examination and a core skill.
Computed tomography
On the other hand, contrast-enhanced thoracic CT-scan images
are commonly able to detect and assess concomitant pneumo-
nia and is the imaging investigation of choice. Thoracic CT allows
not only assessment of the pleura itself, but also chest tube pos-
ition if existing, the presence and degree of loculations, any par-
enchymal changes, endobronchial lesions and differentiation of
lung abscess from empyema. Mostly, CT scan is crucial in the
evaluation of pleural thickening (nodular, mediastinal pleural
thickening suggesting underlying malignancy, circumferential
pleural thickening), can display both visceral and parietal pleural
thickening >1 cm and, in this sense, is fundamental for planning
management strategy according to the expected stage of the
empyema (trapped lung with very ﬁbrotic visceral pleural peel or
loculated early stage empyema). Anyway, we did not ﬁnd CT
helpful in predicting the success of video-assisted thoracoscopic
surgical (VATS) decortication [3].
Bronchoscopy
The role of bronchoscopy in patients with empyema has not been
addressed speciﬁcally by any studies. It is usually performed at the
time of surgery, but only a small number of cases have obstructing
lesions predisposing to empyema (i.e. tumour or inhaled foreign
body). Bronchoscopy is particularly recommended where there is
a mass or volume loss on imaging; nevertheless, sputum removal
prior to decortication will facilitate lung re-expansion.
THE SURGICAL TREATMENT OF ADULT
EMPYEMA
Thoracocentesis
All patients with a pleural effusion in association with sepsis or a
pneumonic illness require a prompt diagnostic pleural ﬂuid sam-
pling, because any effusion identiﬁed on chest X-ray could pos-
sibly turn into a pleural infection, and it is impossible clinically to
differentiate the presence of a complicated parapneumonic effu-
sion requiring chest tube drainage from a simple effusion that
may resolve with antibiotics alone [3].
The role of therapeutic-repeated thoracentesis as an alternative
to formal chest drain placement or an early VATS procedure in
order to prevent ‘empyema stage migration’ in uncomplicated
parapneumonic effusion and early empyema is unknown.
Therapeutic thoracentesis and antibiotics alone have demon-
strated to be successful in one study [3], but thoracocentesis has
not yet been compared with formal drainage in randomized con-
trolled trials and, currently, the evidence suggests its use as a
preoperative crucial diagnostic tool rather than in inﬂuencing sur-
gical management.
Tube thoracostomy
Historically, early stage empyema was managed with tube thora-
costomy with more advanced stages requiring open thoracotomy
and decortication. The current BTS guidelines recommend tube
thoracostomy and antibiotics for the treatment of early stage
empyema, with surgical intervention reserved for failure of these
initial measures in the presence of persistent pleural collection.
The introduction of VATS added new therapeutic techniques to
the armament of surgical strategies, with many surgeons prefer-
ring the VATS approach for the management of empyema.
Currently, there is no consensus on which surgical option is ﬁrst
line. A literature search was performed to investigate whether
VATS decortication is superior to either decortication via thoracot-
omy or simple tube thoracostomy. This search is fully documented
in the Interactive CardioVascular and Thoracic Surgery Journal
(ICVTS) [6] and the results tabulated in Table 3. The majority of
data from surgical series address the management of Stage 2 and
3 empyema.
Summary. In the management of Stage 1 empyema, we are in
agreement with the recommendation of the BTS guideline;
patients with frankly purulent or turbid/cloudy pleural ﬂuid on
sampling should receive prompt pleural space chest tube
drainage. The efﬁcacy of drainage is assessed by a complete lung
expansion and a resolution of symptoms [3].
In the management of Stage 2 and 3 empyema, there is a
demonstrated beneﬁt of surgical debridement or decortication
over tube thoracostomy alone in terms of treatment success and
reduction in hospital stay [6–8] (Fig. 1, Table 4).
Intrapleural ﬁbrinolysis
The use of intrapleural ﬁbrinolytics via tube thoracostomy has
gained recent interest among the thoracic surgical community.
The introduction of ﬁbrinolytic agents into the pleural space is
thought to cleave ﬁbrous septations and improve the drainage of
ﬁbrinopurulent empyema. Although a number of observational
studies report an improved drainage with ﬁbrinolytic use [29–34],
the ﬁrst large multicentre trial (Multicenter Intra-pleural Sepsis
Trial, MIST1 [35]) reported no beneﬁt of intrapleural ﬁbrinolysis
(with streptokinase) and this ﬁnding was further validated by a
meta-analysis [36]. However, the MIST2 trial [37] found that a com-
bination of tissue plasminogen activator (t-PA) and DNase
improved ﬂuid drainage and reduced the frequency of surgical re-
ferral and duration of hospital stay. Although the MIST2 trial con-
ﬁrmed a role for intrapleural ﬁbrinolysis, debate still exists
regarding its efﬁcacy when compared with primary VATS in the
management of ﬁbrinopurulent empyema. A randomized trial
[38] comparing tube thoracostomy with streptokinase (n = 9) with
VATS (n = 11) found that primary intervention with VATS resulted
in higher treatment success (91 vs 44%), lower chest tube duration
(5.8 vs 9.8 days) and decreased total hospital stay (8.7 vs 12.8
days), and this was further demonstrated by observational studies
by Petrakis et al. [39] and Muhammed et al. [9].
Summary. Currently, the speciﬁc role of intrapleural ﬁbrinolysis
is yet to be deﬁned; however, due to the favourable outcomes of
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VATS, it may well be reserved for those patients unsuitable for
surgical intervention and single lung ventilation (Fig. 1, Table 4).
Video-assisted thoracoscopic surgery
The goals of surgery for empyema are: (i) to debride the pleural
cavity and (ii) to achieve lung re-expansion.
Debridement of the pleural cavity comprises drainage of all
ﬂuid, breaking of all loculations and removal of all the pleural
exudate. Decortication entails thorough removal of the restrictive
cortex of ﬁbrous and infected tissue overlying the visceral pleura
to allow the lung to re-expand.
The method of approach by which these goals are achieved
remains controversial and while some surgeons advocate VATS,
others strongly favour an open approach. Studies reporting out-
comes for a mixed population of Stage 2/3 empyema report at
least equivalent outcomes in terms of resolution of disease for
VATS when compared with open surgery [10–15], and many
authors report additional beneﬁts of a minimally invasive ap-
proach including a reduction in operative time [9], postoperative
pain, duration of chest tube [13, 16] and length of hospital stay [9,
13–15]. Other potential beneﬁts include greater satisfaction with
postoperative wound appearance [11, 14] and an earlier return to
work. It must be acknowledged that non-randomized studies may
introduce selection bias, possibly attributing technically more
challenging procedures to an open approach.
The need for intraoperative conversion from VATS to thoracot-
omy correlates with the stage of disease and time from symptom
onset [17]. Higher conversion rates are also associated with male
gender, post-pneumonic empyema and gram-negative organisms
[18]. Lardinois et al. reported that the probability of conversion to
thoracotomy rose from 22 to 86% between an interval of 12 and
16 days, respectively [18].
In the management of Stage 3 disease, VATS has been shown to
be as effective as open decortication in a signiﬁcant proportion of
patients [17, 19, 20] with the associated beneﬁts of a minimally inva-
sive approach. There is, however, the caveat of a high conversion
rate to open decortication, with some series reporting conversion
rates above 40% [20]. Decortication of Stage 3 empyema via VATS
requires a signiﬁcant learning curve and success with VATS corre-
lates with operative experience and skill [20].
Figure 1:Management of empyema in the adult. VATS: video-assisted thoracoscopic surgery.
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Table 4: Studies detailing the management of pleural empyema in the adult
Study Stage of
empyema
Procedure (no. of
patients)
Operative time (min) Chest tube
drainage (days)
Postoperative length of
stay (days)—mean unless
stated
Postoperative
morbidity
Procedure
success
Reintervention Mortality Conversion
rate
VATS versus thoracotomy
Muhammed [9]
Prospective
Stage 2/3 VATS (25) 84.68 ± 23.98 5.72 ± 3.27 7.76 ± 4.63 – 92% 0% 0% 8%
Open (24) 137.37 ± 26.9 7.25 ± 2.31 8.87 ± 2.59 – 100% 0% 0%
Cardillo [10]
Retrospective
Stage 2/3 VATS (185) 79.7 ± 6.8 – 8.6 ± 1.8 18.3% 98.4% 1.62% 0% 5.9%
Open (123) 70.0 + 7.4 – 10 ± 7.8 25.2% 100% 4.8% 3.3%
Chan [11]
Prospective
Stage 2/3 VATS (41) 150 ± 57.6 7.9 ± 5.7 16 ± 6.5 22%a 100% 0% 0% 0%
Open (36) 228 ± 84 8.5 ± 4.4 21 ± 14.2 100% 0% 0%
Tong [12]
Retrospective
Stage 2/3 VATS (326) 97 7.0 ± 13.7 7b – 92.3% 7.7% 7.6% 11.4%
Open (94) 155 9.7 ± 10.1 10b – 89.4% 10.6% 16.1%
Casali [13]
Retrospective
Stage 2 VATS (27) 100.4 4.0 6.4 24%a 100% – 0% 8%
Open (24) 115.4 7.3 9.0 100% – 0%
Stage 3 Open (68) 131.5 5.7 14.6 97.1% – 2.94%
Angelillo [14]
Retrospective
Stage 2 VATS (31) 119 ± 32.5 4.3 ± 1.5 6.7 ± 3.0 16.1% 100% 0% 3.2% 10%
Open (33) 123 ± 25.8 6.1 ± 2.3 11.6 ± 9.1 15.1% 88% 12% 3%
Marks [15]
Retrospective
Stage 2/3 VATS (116) – – 5b 25.1%a 95.1%a – 5.7%* 14.7%
Open (277) – – 7b
Podbielski [16]
Retrospective
Stage 2/3 VATS (16) 76.2 ± 30.7 4.7 ± 2.8 17.6 ± 16.8 6.25% – – – 6.7%
Open (14) 125.0 ± 71.7 8.3 ± 4.6 10.0 ± 7.2 7.14% – – –
Chung [17]
Retrospective
Stage 3 VATS (14) 138.6 ± 52.1 10 ± 4.2 13.5 ± 6.4 – 92.9% 7.1% 0% 0%
Open (8) 299.4 ± 74.7 18.75 ± 19.8 19 ± 12.8 – – – –
Lardinois [18]
Retrospective
Stage 2/3 VATS (178) – – – 9%a 56% 2% 3% 44%
Open (150) – – – 97.4% 2.6% 4%
Shahin [19]
Retrospective
Stage 2 VATS debridement (28) – – 6b 3.5% – – 0% 0%
Stage 3 VATS decortication (32) – – 5b 9.3% – – 0% 19%
Stage 2/3 Open (21) – – 8b 26.1% – – 0% –
Waller [20]
Retrospective
Stage 3 VATS decortication (21) 78.8 ± 6.5 – 5.5 ± 0.6 – 100% 0% 4.8% 41.7%
Open–converted (15) 119.6 ± 13.5 – 8.5 ± 1.3 – 100% 0% 6.7%
Primarily open (12) 109 ± 5.5 – 8.4 ± 0.7 – 100% 0% 0%
Series of VATS for management of empyema
Stefani [21]
Retrospective
Stage 2/3 VATS (97) 146 4.4 8.3 5% 100% – 0% 59%
Converted to open 162 5.0 8.4 18%
Solaini [22]
Retrospective
Stage 2/3 110 – 6.0 7.1 11% 99.1% – – 8.2%
Drain [23]
Retrospective
Stage 3 52 – 3.9 10b 0% 94% 6% 0% 0%
Luh [17]
Retrospective
Stage 2/3 234 64.3 ± 22.5 7b 12b 7.7% 86.3% 6.8% 3.4% 10.3%
Kim [24]
Retrospective
Stage 2/3 70 – 5 ± 3 5 ± 0.7 0% 92.9% – 0% 7.1%
Roberts [25]
Retrospective
Stage 2/3 VATS (172) – 10.5 15.3 9% 38.4% 3.0% 0% 61.6%
Converted to open 21% 97.2% 2.8% 10.4%
Striffeler [26]
Retrospective
Stage 2 67 82.1 4.1 12.3 – – 4% 4% 28%
Lawrence [27]
Retrospective
Stage 2/3 VATS (42) – 4.0 ± 0.3 5.3 ± 0.4 – 71.4% 23.8% 0 4.8%
Converted to open 8.5 ± 2.0 10.3 ± 2.1
Chung [17]
Retrospective
Stage 2/3 120 111.9 7.4 10.0 – 95.8% 4.2% 0% 1.4%
Landreneau [28]
Retrospective
Stage 2/3 76 – 3.3 ± 2.9 (in 67
patients)
7.4 ± 7.2 – 83% 7.9% 6.6% 17%
aStudy did not differentiate outcomes between the VATS and open group.
bMedian values.
M
.Scarcietal./
European
JournalofC
ardio-Thoracic
Surgery
646
Interestingly, Kho et al. [40] recently published a study compar-
ing debridement and formal decortication. Sixteen patients
underwent debridement by a limited thoracotomy and 9 decorti-
cation via full thoracotomy. There was a 30% reduction in cavity
size on discharge in both groups and equivalent results at the
45-day follow-up. It is therefore reasonable to consider a primary
VATS approach in both Stage 2 and Stage 3 empyema in patients
who are ﬁt for surgery.
Early surgical referral is advised for successful VATS and the
delay in surgical intervention has been shown to have an impact
on empyema stage migration. Several authors have documented
that time of referral is the most common and independent factor
affecting rate of conversion from VATS to open thoracotomy [10,
18, 22, 23, 24 17]. One study demonstrated that the probability of
thoracotomy increased from 28% if the operation was performed
within 10 days from the onset of symptoms to 81% if it was per-
formed with a delay of between 30 and 40 days [25].
Summary. In summary, the current literature cements the role
of VATS in the management of pleural empyema. While there
is signiﬁcant heterogeneity between studies, with discrepancies
in the deﬁnition of debridement/decortication, stage and aetiology
of empyema, all studies demonstrate successful management with
VATS [25–28, 41–44] Many reports suggest additional beneﬁts over
open surgery or tube thoracostomy with or without ﬁbrinolytic
agents. Ultimately, the choice of surgical approach relies on the
individual surgeon’s preference, with many advocates of open
decortication stating completeness of decortication as their
motivation. In conclusion, there is nothing to be lost in attempting
VATS in all cases, provided that conversion to open thoracotomy is
performed if resolution of the empyema and lung expansion is
not adequately achieved (Fig. 1, Table 4).
Thoracotomy
The exact placement of the open incision can be planned from
preoperatively especially in the presence of a loculated empyema.
Open surgery should include evacuation of all purulent material
and thorough decortication of the parietal and visceral pleura to-
gether with complete separation of the diaphragm from the lung.
Attention should be directed to the complete enucleation of the
infected sac: ‘empyemectomy’.
This is best achieved through extra-pleural dissection and is a
safe and time-saving procedure.
Empyemectomy is difﬁcult to achieve by VATS; nevertheless, in
the light of the great majority of the works in the recent literature,
the minimally invasive approach could represent the treatment of
choice for pleural empyema.
Tuberculosis (TB)-related empyema remains an area in which
there is no level A evidence to guide practice; suggested indications
include cancer, destroyed lung, haemoptysis, multidrug-resistant TB,
pleural disease and aspergilloma [45]. More recently, larger series
(1297 operative cases) with promising results (1.37% early and 2.83%
late mortality after the exclusion of window thoracostomy) have pro-
vided more compelling evidence for the incorporation of surgical
treatment into practice guidelines and recommendations [46].
Summary. In summary, the current literature supports the use of
VATS as the initial step at least for exploration and evacuation of
necrotic material from the cavity (debridement). Visceral decortication
and ‘empyemectomy’ can be technically demanding and even in
the presence of a reported high success rate for VATS (from 68 to
93%), there should be increased awareness of its limitations in
patients with a symptomatic history over 5 weeks (presumed
Stage III) (Fig. 1, Table 1).
EMPYEMA IN CHILDREN
In the management of empyema in the paediatric population, the
optimal ﬁrst-line therapeutic strategy remains controversial. A
best evidence topic was performed to investigate whether VATS
decortication is superior to either decortication via thoracotomy
or simple tube thoracostomy [47]. The literature search failed to
show deﬁnitive signiﬁcant advantages of surgery over conservative
chest tube drainage.
On the basis of the reported studies, we concluded that early
VATS (or thoracotomy if VATS is not possible) leads to shorter hos-
pitalization [47]. Streptococcus pneumoniae remains one of the
most common causative organisms of empyema, particularly in
the developed world and especially so in children [48]. The
current management guidelines, as published by the British
Thoracic Society [3], reserve surgical intervention as an adjunct to
antibiotic therapy either when maximal antibiotic therapy has not
been sufﬁcient or when there is some associated lung pathology,
related complications or sepsis. Currently, there is no deﬁnitive
evidence to suggest that early surgical management may be indi-
cated based purely on the causative pathogen.
The argument for primary surgery
A systematic review of 44 retrospective studies involving 1369
patients concluded that early VATS or thoracotomy was associated
with a shorter hospital stay and a trend towards shorter duration
of postoperative fever when compared with tube thoracostomy
alone or in combination with ﬁbrinolytic therapy [49]. The beneﬁt
of primary operative therapy was echoed by a meta-analysis of 67
studies, which concluded that primary operative intervention is
associated with a lower in-patient mortality, reintervention rate,
hospital stay, duration of tube thoracostomy and duration of anti-
biotic therapy when compared with non-operative management
[50]. Subsequently, a number of retrospective studies have further
described the beneﬁts of primary surgical intervention. It should
be noted that, in children, tube thoracostomy may require sed-
ation or even anaesthesia. Therefore, VATS should be considered if
the patient is so prepared [51–56].
The argument for primary non-operative
treatment
However, contrasting retrospective series have reported successful
outcomes with primary non-operative management [57–59] and a
subsequent review of the literature concluded that the main steps
in treatment are percutaneous drainage with consideration of ﬁ-
brinolysis, with VATS reserved for failure of initially non-operative
management [60]. Three randomized control trials compared
VATS with chest drainage with ﬁbrinolytics and found no signiﬁ-
cant difference in outcomes in two of the three trials [61].
Sonnappa et al. [62] and St Peter et al. [63] used small (8–12
French) chest drains with routine administration of ﬁbrinolytics,
whereas Kurt et al. [64] used larger chest drains (16–24 French) and
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administered ﬁbrinolytics as a rescue therapy based on imaging
and drainage. The study by Kurt et al. was stopped early owing to
an observed beneﬁt in the mean hospital stay (5.8 ± 2.8 vs 13.2 ± 7.2
days, P < 0.01) with VATS. Hospital stays were equivalent between
VATS and chest drain with ﬁbrinolytics in the other two studies (St
Peter: 6.9 ± 3.7 vs 6.8 ± 2.9 days; Sonnappa: 6 vs 6 days, respectively).
St Peter later reported successful implementation of an evidence-
based protocol using ﬁbrinolysis as the ﬁrst-line treatment for
empyema in children; 16 of 102 patients required subsequent VATS
[59]. Proponents of VATS suggest that VATS may reduce cytokine
responses compared with conventional surgery [40].
Summary
In conclusion, the current evidence suggests the primary operative
management with VATS is a safe and effective method of treating
empyema in children; however, non-operative management with
tube thoracostomy and ﬁbrinolytics has been shown to be equally
successful in some populations. It is therefore reasonable to
manage patients with either treatment strategy based upon local
expertise and success rates.
The role of VATS as ‘primary surgical treatment’ as the ﬁrst-line
approach for empyema in paediatric patients remains unclear.
Although the few randomized trials in paediatric patients failed
to show deﬁnitive signiﬁcant advantages of surgery over conser-
vative chest tube drainage, one might argue that, in the vast ma-
jority of paediatric conditions, tube thoracostomy could require
sedation or even general anaesthesia for proper insertion and
intrapleural agent therapy. In this regard, VATS seems a reason-
able alternative and patients may be more likely to fail rescue
VATS treatment following ﬁbrinolytic agents, as it is suggested
that urokinase causes intrapleural loculations to become very ad-
hesive and increases the difﬁculty of a subsequent VATS proced-
ure [49] (Fig. 2, Table 5).
POST-PNEUMONECTOMY EMPYEMA
A best evidence topic was performed to investigate the best treat-
ment for PPE [65]. A literature search showed that an open surgical
approach has a high success rate, low hospital stay and low rein-
tervention rate despite its use in arguably more challenging
Figure 2:Management of empyema in children. VATS: video-assisted thoracoscopic surgery.
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Table 5: Studies detailing the management of pleural empyema in children
Study Stage of
empyema
Procedure (no. of patients) Operative
time (min)
Chest tube
drainage (days)
Postoperative
length of stay
(days)—mean
unless stated
Postoperative
morbidity
Procedure
success
Reintervention Mortality Conversion
rate
Gates [42]
Systematic review
All stages Tube thoracostomy = 611 N/A – 16.4 – 75% 25% – –
Primary fibrinolytic = 83 N/A – 18.9 – – – – –
Thoracotomy = 226 – – 9.9 – – – – –
VATS = 449 – – 10.5 – – – – –
Avansino [43]
Meta-analysis
All stages Non-operative = 3418 N/A 10.6 ± 3.4 20.0 ± 8.3 5.6% 76.4% – 3.3% N/A
Primary operative = 363 – 4.4 ± 1.6 10.8 ± 4.8 5% 97.5% – 0% 1.1%
Primary fibrinolytic = 64 N/A – 10.6 ± 5.1 12.5% 90.7% – 0% N/A
Aziz [44]
Retrospective
All stages Thoracostomy = 21 – – – – – – – N/A
Thoracostomy, then VATS = 15 – – 18 ± 3a – – – – –
Primary VATS = 13 – – 11 ± 0.8a – – – – –
Meirer [40]
Retrospective
All stages VATS = 151 – – 10.1 13.8% 95.4% 4.6% 1.3% –
Schneider [45]
Retrospective
All stages Thoracocentesis/
thoracostomy = 30
N/A – 19a – 62.5% 37.5% – N/A
Secondary VATS = 18 – 7.7 10.3 (15a) – – – – 6%
Primary VATS = 31 – 4.2 7.43 (10.5a) – – – –
Li [46]
Retrospective
All stages Non-operative = 953 N/A – 13.6 8.9% 60.7% 39.3% 1.0% N/A
Primary operative = 220 – – 9.8 8.6% 94.5% 5.5% 0% –
Shah [47] All stages Thoracostomy (714) – – 10b – – – – N/A
VATS (50) – – 7b – – – – –
Bishay [48]
Retrospective
All stages VATS = 114 90b 4b 7b 6% 91% 2.6% 0% 4.4%
Carter [49]
Retrospective
All stages Antibiotics = 95 – – 7.0 ± 3.5a 0% 99.0% 1.1% 0% –
Drainage procedures = 87 – – 11.0 ± 4.0a 6.9% – – 0% –
Grisaru-Soen [50]
Retrospective
All stages Thoracostomy = 20 – – 14.08a – – – 0% N/A
Thoracostomy + fibrinolysis = 16 – – 15.9a – – – 0% N/A
VATS = 11 – – 14.2a – – – 0% –
Gasior [51]
Retrospective
All stages Fibrinolysis = 102 N/A – 7.2 ± 3.2 0% 84.3% 15.7% 0% N/A
Sonnappa [54]
Prospective RCT
All stages Fibrinolytics = 30 N/A – 6b 0% 82.1% 17.9% 0% N/A
VATS = 30 – – 6b 0% 83.4% 3.3% 0% 13.3%
St Peter [55]
Prospective RCT
All stages Fibrinolytics = 18 N/A – 6.8 ± 2.9 0% 83.4% 16.6% 0% N/A
VATS = 18 – – 6.9 ± 3.7 11.1% 100% 0% 0% –
Kurt [56]
Prospective RCT
All stages Thoracostomy ± fibrinolytic = 8 N/A 9.6 ± 5.5 13.3 ± 7.2 0% 100% 37.5% 0% N/A
VATS = 10 47.4 ± 14.6 2.8 ± 0.6 5.8 ± 2.8 0% 100% 0% 0% 0%
aTotal hospital length of stay.
bMedian length of stay.
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situations. This suggests that an open surgical approach may be
more effective than minimally invasive options in treating patients
with PPE [65] (Fig. 3).
The management of PPE ranges from minimally invasive surgi-
cal techniques such as VATS debridement to fenestration to exten-
sive open procedures involving myoplastic and thoracoplastic
techniques. Operative approach is largely guided by the presence
or absence of a bronchopleural ﬁstula (BPF), which requires more
aggressive surgical intervention. A BPF is found in >80% of patients
[65]. The surgical principles include control of pleural space infec-
tion by drainage, debridement or by space obliteration and—in
case of a ﬁstula—closure of the BPF with a vascularized ﬂap.
Control of pleural space infection has been achieved by different
techniques, such as pleural drainage lavage, thoracotomy and
removal of necrotic tissue associated with open pleural packing
for many weeks followed by obliteration of the empyema space
with antibiotic ﬂuid or muscle, or pleural space irrigation followed
by obliteration of the pleural space with an antibiotic solution [65].
Published series of PPE often report a mixed cohort of patients
with or without ﬁstulae, with many institutional reviews involving
the sequential use of interventions according to local practice.
This heterogeneity of the existing literature makes detailed com-
parison of interventions challenging [65].
Thoracostomy and open debridement
In 1979, Goldstraw [66] reported a series of PPEs managed by fen-
estration, based on previous techniques described by Eloesser [67]
and Clagett and Geraci [68]. Fenestration was performed under
general anaesthesia, opening the middle third of the previous
thoracotomy wound and removing 6–8 cm of the underlying rib
Figure 3:Management of post-pneumonectomy empyema.
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and up to three of the adjacent ribs; the skin edges where then
sutured to the parietal pleura to create a skin-lined fenestra. The
success rate of this series was 77% in keeping with earlier reports
detailing fenestration for PPE [68–70]. Further series have con-
ﬁrmed the high success rate (81%); however, they have also high-
lighted a high morbidity (55%) and mortality (7.1%) associated
with the procedure [71] and demonstrated a beneﬁt of early inter-
vention [72]. Goldstraw and colleagues later reported a second
series detailing the management of simple PPE with rib resection,
tube thoracostomy and irrigation with good success rates,
Video-assisted thoracoscopic surgical debridement
Over the past decade, the new techniques have been introduced
for the management of PPE with the continuing aim of reducing
the associated morbidity and mortality. VATS debridement has
been shown to be effective in the management of PPE (in the
absence of BPF or in the presence of microﬁstula) with good
success rates and low associated morbidity or mortality [73, 74].
Thoracoplasty
Thoracoplasty is rarely indicated nowadays, but this does not imply
that the procedure should be avoided, especially as less extensive
thoracoplastic procedures are possible. Complete space obliteration
may be achieved by combining a thoracoplasty conﬁned to a few
rib segments and intrathoracic-restricted muscle ﬂap transposition.
The disadvantages of thoracoplasty are progressive scoliosis,
chronic postoperative pain and ‘mutilating’ cosmetic appearance.
Vacuum-assisted closure
A search for evidence was performed to investigate whether
vacuum-assisted closure (VAC) therapy could increase the speed of
recovery in patients with an open wound after lung resection. This
search is fully documented in the ICVTS [75]. All papers were retro-
spective and included a total of 69 patients treated with intrathor-
acic VAC. The technique involves the packing of the intrathoracic
cavity with polyurethane foam (the mediastinum and the bronchus
can be covered using polyvinyl alcohol foam) and application of a
negative pressure of −25 to −75 mmHg, which is adjusted de-
pending on the presence or absence of signs of mediastinal trac-
tion. The pressure can be gradually decreased to −125 mmHg over
time, with regular VAC changes every 2–5 days. One cohort study
reported a signiﬁcantly shorter duration of open window thoracost-
omy in those managed with VAC (39 ± 17 days) compared with
those managed without VAC (933 ± 1422 days) [74]. A second study
reported the median length of VAC treatment as 22 days (range 6–
66 days) [76]. Interestingly, Groetzner et al. [77] reported the safe use
of VAC in patients with BPF after covering the bronchus stump with
an intrathoracic muscle ﬂap. This accumulating evidence, though
limited, suggests that VAC as an adjunct to the standard treatment
can potentially alleviate the morbidity and decrease hospital stay in
patients with empyema after lung resection.
Direct bronchopleural ﬁstula repair
In contrast, Gharagozloo et al. [78] reported a 100% success rate
for patients with PPE and BPF managed with direct repair and
pleural space irrigation, followed by obliteration of the space with
an antibiotic solution. The mean hospital stay was 12.9 days, and
there was no recurrence of the empyema at the 1-year follow-up.
The pedicled greater omentum or a pedicled diaphragmatic
muscle ﬂap can be used to buttress the bronchial stump.
Muscle interposition
Myoplasty has a dual role either in the direct closure of BPF or as a
secondary process due to pleural space obliteration. Cases compli-
cated by ﬁstulae required complex individualized surgery [79]. This
was reinforced in two further series, which demonstrated superior
success rates with more radical approaches involving myoplasty and
thoracoplasty [80, 81]. Vast majority of reports favour the use of
extrathoracic muscle ﬂaps to cover the ﬁstula (latissimus dorsi or part
of it, pectoralis major, serratus anterior, trapezius and the rhomboid
muscles, depending on the location of the space to be obliterated).
There is general consensus that myoplasty should be performed
in a clean environment, as in the presence of gross sepsis, a failure
rate of 25% has been reported.
Accelerated regimen
In 2008, Schneiter reported a series of 75 patients managed with
an accelerated regimen, of thoracotomy with radical debridement
followed by packing with povidone–iodine dressings, repeated
every second day. Any BPF was repaired with direct closure and/
or reinforcement with muscle ﬂap/omental patch. The group
reported an 86.7% success rate and a mortality rate of 1.3%.
Patients returned to theatre an average of 3 times and the chest
deﬁnitively closed in 94.6% within 8 days [74].
Apart from the disadvantages of repeated surgical and general
anaesthesia sessions, the authors report the following beneﬁts:
between debridements there are no painful dressing changes in the
ward; (because the chest is closed and is water- and airtight) re-
spiratory mechanics are not impaired; patients also remain mobile
and proﬁt from physiotherapy; the procedure greatly improves in-
dependent bodily hygiene and spares patients the burden of an
open chest wound. In some cases, it might have been possible to
achieve successful healing with fewer surgical interventions.
Summary
In summary, the management of PPE is greatly determined by the
presence or absence of associated ﬁstulae. In simple PPE with no
associated ﬁstulae, minimally invasive methods such as VATS de-
bridement or pleural space irrigation via large bore tube thoracost-
omy or fenestration are associated with good success rates.
Complex empyema spaces associated with ﬁstulae require complex
individualized surgical strategies, which are dependent upon indi-
vidual patient characteristics and different local practice (Table 4).
Conﬂict of interest: none declared.
REFERENCES
[1] Ferguson AD, Prescott RJ, Selkon JB, Watson D, Swinburn CR. The clinical
course and management of thoracic empyema. QJM 1996;89:285–9.
[2] Finley C, Clifton J, Fitzgerald JM, Yee J. Empyema: an increasing concern in
Canada. Can Respir J 2008;15:85–9.
R
EP
O
R
T
M. Scarci et al. / European Journal of Cardio-Thoracic Surgery 651
[3] Davies HE, Davies RJ, Davies CW. Management of pleural infection in
adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax
2010;65(Suppl 2):ii41–53.
[4] Dunning J, Prendergast B, Mackway-Jones K. Towards evidence-based
medicine in cardiothoracic surgery: best BETS. Interact CardioVasc Thorac
Surg 2003;2:405–9.
[5] Kolh P, Wijns W, Danchin N, Di Mario C, Falk V, Folliguet T et al. Guidelines
on myocardial revascularization. Eur J Cardiothorac Surg 2010;38(Suppl):
S1–S52.
[6] Chambers A, Routledge T, Dunning J, Scarci M. Is video-assisted thoraco-
scopic surgical decortication superior to open surgery in the management
of adults with primary empyema? Interact CardioVasc Thorac Surg 2010;
11:171–7.
[7] Mandal AK, Thadepalli H, Chettipally U. Outcome of primary empyema
thoracis: therapeutic and microbiologic aspects. Ann Thorac Surg 1998;66:
1782–6.
[8] Bilgin M, Akcali Y, Oguzkaya F. Beneﬁts of early aggressive management of
empyema thoracis. ANZ J Surg 2006;76:120–2.
[9] Muhammad MI. Management of complicated parapneumonic effusion
and empyema using different treatment modalities. Asian Cardiovasc
Thorac Ann 2012;20:177–81.
[10] Cardillo G, Carleo F, Carbone L, Di Martino M, Salvadori L, Petrella L et al.
Chronic postpneumonic pleural empyema: comparative merits of thoraco-
scopic versus open decortication. Eur J Cardiothorac Surg 2009;36:914–8.
[11] Chan DT, Sihoe AD, Chan S, Tsang DS, Fang B, Lee TW et al. Surgical treat-
ment for empyema thoracis: is video-assisted thoracic surgery ‘better’
than thoracotomy? Ann Thorac Surg 2007;84:225–31.
[12] Tong BC, Hanna J, Toloza EM, Onaitis MW, D’Amico TA, Harpole DH et al.
Outcomes of video-assisted thoracoscopic decortication. Ann Thorac Surg
2010;89:220–5.
[13] Casali C, Storelli ES, Di Prima E, Morandi U. Long-term functional results
after surgical treatment of parapneumonic thoracic empyema. Interact
CardioVasc Thorac Surg 2009;9:74–8.
[14] Angelillo Mackinlay TA, Lyons GA, Chimondeguy DJ, Piedras MA,
Angaramo G, Emery J. VATS debridement versus thoracotomy in the treat-
ment of loculated postpneumonia empyema. Ann Thorac Surg 1996;61:
1626–30.
[15] Marks DJ, Fisk MD, Koo CY, Pavlou M, Peck L, Lee SF et al. Thoracic
empyema: a 12-year study from a UK tertiary cardiothoracic referral
centre. PLoS One 2012;7:e30074.
[16] Podbielski FJ, Maniar HS, Rodriguez HE, Hernan MJ, Vigneswaran WT.
Surgical strategy of complex empyema thoracis. JSLS. 2000;4:287–90.
[17] Chung JH, Lee SH, Kim KT, Jung JS, Son HS, Sun K. Optimal timing of thoraco-
scopic drainage and decortication for empyema. Ann Thorac Surg 2014;97:
224–9.
[18] Lardinois D, Gock M, Pezzetta E, Buchli C, Furrer M, Ris HB. Delayed refer-
ral and gram-negative organisms increase the conversion thoracotomy
rate in patients undergoing video-assisted thoracoscopic surgery for
empyema. Ann Thorac Sur 2005;79:1851–6.
[19] Shahin Y, Duffy J, Beggs D, Black E, Majewski A. Surgical management of
primary empyema of the pleural cavity: outcome of 81 patients. Interact
CardioVasc Thorac Surg 2010;10:565–7.
[20] Waller DA, Rengarajan A. Thoracoscopic decortication: a role for
video-assisted surgery in chronic postpneumonic pleural empyema. Ann
Thorac Surg 2001;71:1813–6.
[21] Storm HK, Krasnik M, Bang K, Frimodt-Moller N. Treatment of pleural
empyema secondary to pneumonia: thoracocentesis regimen versus tube
drainage. Thorax 1992;47:821–4.
[22] Waller DA, Rengarajan A, Nicholson FHG, Rajesh PB. Delayed referral
reduces the success of video-assisted thoracoscopic debridement for
post-pneumonic empyema. Respir Med 2001;95:836–40.
[23] Roberts JR. Minimally invasive surgery in the treatment of empyema:
intraoperative decision making. Ann Thorac Surg 2003;76:225–30.
[24] Chapman SJ, Davies RJ. The management of pleural space infections.
Respirology 2004;9:4–11.
[25] Stefani A, Aramini B, Della Casa G, Ligabue G, Kaleci S, Casali C et al.
Preoperative predictors of successful surgical treatment in the manage-
ment of parapneumonic empyema. Ann Thorac Surg 2013;96:1812–9.
[26] Solaini L, Prusciano F, Bagioni P. Video-assisted thoracic surgery in the
treatment of pleural empyema. Surg Endosc 2007;21:280–4.
[27] Drain AJ, Ferguson JI, Sayeed R, Wilkinson S, Ritchie A. Deﬁnitive manage-
ment of advanced empyema by two-window video-assisted surgery.
Asian Cardiovasc Thorac Ann 2007;15:238–9.
[28] Luh SP, Chou MC, Wang LS, Chen JY, Tsai TP. Video-assisted thoracoscopic
surgery in the treatment of complicated parapneumonic effusions or
empyemas: outcome of 234 patients. Chest 2005;127:1427–32.
[29] Davies RJ, Traill ZC, Gleeson FV. Randomised controlled trial of intrapleural
streptokinase in community acquired pleural infection. Thorax 1997;52:
416–21.
[30] Bouros D, Schiza S, Tzanakis N, Chalkiadakis G, Drositis J, Siafakas N.
Intrapleural urokinase versus normal saline in the treatment of compli-
cated parapneumonic effusions and empyema: a randomized, double-
blind study. Am J Respir Crit Care Med 1999;159:37–42.
[31] Tuncozgur B, Ustunsoy H, Sivrikoz MC, Dikensoy O, Topal M, Sanli M et al.
Intrapleural urokinase in the management of parapneumonic empyema: a
randomised controlled trial. Int J Clin Pract 2001;55:658–60.
[32] Talib SH, Verma GR, Arshad M, Tayade BO, Rafeeque A. Utility of intra-
pleural streptokinase in management of chronic empyemas. J Assoc Phys
India 2003;51:464–8.
[33] Diacon AH, Theron J, Schuurmans MM, Van de Wal BW, Bolliger CT.
Intrapleural streptokinase for empyema and complicated parapneumonic
effusions. Am J Respir Crit Care Med 2004;170:49–53.
[34] Misthos P, Sepsas E, Konstantinou M, Athanassiadi K, Skottis I, Lioulias A.
Early use of intrapleural ﬁbrinolytics in the management of empyema: a
prospective study. Eur J Cardiothorac Surg 2005;28:599–603.
[35] Maskell NA, Davies CWH, Nunn AJ, Hedley EL, Gleeson FV, Miller R et al.
U.K. controlled trial of intrapleural streptokinase for pleural infection. N
Engl J Med 2005;352:865–74.
[36] Tokuda Y, Matsushima D, Stein GH, Miyagi S. Intrapleural ﬁbrinolytic
agents for empyema and complicated parapneumonic effusions: a
meta-analysis. Chest 2006;129:783–90.
[37] Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C et al.
Intrapleural use of tissue plasminogen activator and DNase in pleural in-
fection. N Engl J Med 2011;365:518–26.
[38] Wait MA, Sharma S, Hohn J, Dal Nogare A. A randomized trial of
empyema therapy. Chest 1997;111:1548–51.
[39] Petrakis IE, Kogerakis NE, Drositis IE, Lasithiotakis KG, Bouros D, Chalkiadakis
GE. Video-assisted thoracoscopic surgery for thoracic empyema: primarily,
or after ﬁbrinolytic failure? Am J Surg 2004;187:471–4.
[40] Kho P, Karunanantham J, Leung M, Lim E. Debridement alone without de-
cortication can achieve lung re-expansion in patients with empyema: an
observational study. Interact CardioVasc Thorac Surg 2011;12:724–7.
[41] Kim BY, Oh BS, Jang WC, Min YI, Park YK, Park JC. Video-assisted thoraco-
scopic decortication for management of postpneumonic pleural
empyema. Am J Surg 2004;188:321–4.
[42] Striffeler H, Gugger M, Im Hof V, Cerny A, Furrer M, Ris HB. Video-assisted
thoracoscopic surgery for ﬁbrinopurulent pleural empyema in 67 patients.
Ann Thorac Surg 1998;65:319–23.
[43] Lawrence DR, Ohri SK, Moxon RE, Townsend ER, Fountain SW.
Thoracoscopic debridement of empyema thoracis. Ann Thorac Surg 1997;
64:1448–50.
[44] Landreneau RJ, Keenan RJ, Hazelrigg SR, Mack MJ, Naunheim KS.
Thoracoscopy for empyema and hemothorax. Chest 1996;109:18–24.
[45] Pezzella AT, Fang W. Surgical aspects of thoracic tuberculosis: a contem-
porary review. Curr Probl Surg 2008;45:715.
[46] Dewan RK. Surgery for pulmonary tuberculosis. A 15-year experience. Eur
J Cardiothorac Surg 2010;37:473–7.
[47] Scarci M, Zahid I, Bille A, Routledge T. Is video-assisted thoracoscopic
surgery the best treatment for paediatric pleural empyema? Interact
CardioVasc Thorac Surg 2011;13:70–6.
[48] Sakran W, Ababseh Zel D, Miron D, Koren A. Thoracic empyema in chil-
dren: clinical presentation, microbiology analysis and therapeutic options.
J Infect Chemother 2014;20:262–5.
[49] Gates RL, Caniano DA, Hayes JR, Arca MJ. Does VATS provide optimal
treatment of empyema in children? A systematic review. J Pediatr Surg
2004;39:381–6.
[50] Avansino JR, Goldman B, Sawin RS, Flum DR. Primary operative versus
nonoperative therapy for pediatric empyema: a meta-analysis. Pediatrics
2005;115:1652–9.
[51] Aziz A, Healey JM, Qureshi F, Kane TD, Kurland G, Green M et al.
Comparative analysis of chest tube thoracostomy and video-assisted thor-
acoscopic surgery in empyema and parapneumonic effusion associated
with pneumonia in children. Surg Infect (Larchmt) 2008;9:317–23.
[52] Meier AH, Hess CB, Cilley RE. Complications and treatment failures of
video-assisted thoracoscopic debridement for pediatric empyema.
Pediatr Surg Int 2010;26:367–71.
[53] Schneider CR, Gauderer MW, Blackhurst D, Chandler JC, Abrams RS.
Video-assisted thoracoscopic surgery as a primary intervention in pediat-
ric parapneumonic effusion and empyema. Am Surg 2010;76:957–61.
[54] Li ST, Gates RL. Primary operative management for pediatric empyema:
decreases in hospital length of stay and charges in a national sample. Arch
Pediatr Adolesc Med 2008;162:44–8.
M. Scarci et al. / European Journal of Cardio-Thoracic Surgery652
[55] Shah SS, Ten Have TR, Metlay JP. Costs of treating children with compli-
cated pneumonia: a comparison of primary video-assisted thoracoscopic
surgery and chest tube placement. Pediatr Pulmonol 2010;45:71–7.
[56] Bishay M, Short M, Shah K, Nagraj S, Arul S, Parikh D et al. Efﬁcacy of
video-assisted thoracoscopic surgery in managing childhood empyema: a
large single-centre study. J Pediatr Surg 2009;44:337–42.
[57] Carter E, Waldhausen J, Zhang W, Hoffman L, Redding G. Management of
children with empyema: pleural drainage is not always necessary. Pediatr
Pulmonol 2010;45:475–80.
[58] Grisaru-Soen G, Eisenstadt M, Paret G, Schwartz D, Keller N, Nagar H et al.
Pediatric parapneumonic empyema: risk factors, clinical characteristics,
microbiology, and management. Pediatr Emerg Care 2013;29:425–9.
[59] Gasior AC, Knott EM, Sharp SW, Ostlie DJ, Holcomb GW III, St Peter SD.
Experience with an evidence-based protocol using ﬁbrinolysis as ﬁrst line
treatment for empyema in children. J Pediatr Surg 2013;48:1312–5.
[60] Paraskakis E, Vergadi E, Chatzimichael A, Bouros D. Current evidence for
the management of paediatric parapneumonic effusions. Curr Med Res
Opin 2012;28:1179–92.
[61] Mahant S, Cohen E, Weinstein M, Wadhwa A. Video-assisted thoraco-
scopic surgery vs chest drain with ﬁbrinolytics for the treatment of pleural
empyema in children: a systematic review of randomized controlled trials.
Arch Pediatr Adolesc Med 2010;164:201–3.
[62] Sonnappa S, Cohen G, Owens CM, van Doorn C, Cairns J, Stanojevic S
et al. Comparison of urokinase and video-assisted thoracoscopic surgery
for treatment of childhood empyema. Am J Respir Crit Care Med 2006;
174:221–7.
[63] St Peter SD, Tsao K, Spilde TL, Keckler SJ, Harrison C, Jackson MA et al.
Thoracoscopic decortication vs tube thoracostomy with ﬁbrinolysis for
empyema in children: a prospective, randomized trial. J Pediatr Surg 2009;
44:106–11; discussion 111.
[64] Kurt BA, Winterhalter KM, Connors RH, Betz BW, Winters JW. Therapy of
parapneumonic effusions in children: video-assisted thoracoscopic surgery
versus conventional thoracostomy drainage. Pediatrics 2006;118:e547–53.
[65] Zahid I, Routledge T, Bille A, Scarci M. What is the best treatment of post-
pneumonectomy empyema? Interact CardioVasc Thorac Surg 2011;12:
260–4.
[66] Goldstraw P. Treatment of postpneumonectomy empyema: the case for
fenestration. Thorax 1979;34:740–5.
[67] Eloesser L. An operation for tuberculous empyema. Surg Gynaecol Obstet
1935;60:1096–7.
[68] Clagett OT, Geraci JE. A procedure for the management of postpneumo-
nectomy empyema. J Thorac Cardiovasc Surg 1963;45:141–5.
[69] Adler RH, Plaut ME. Postpneumonectomy empyema. Surgery 1972;71:210–4.
[70] Conklin WS. Postpneumonectomy empyema, single-stage operative treat-
ment. J Thorac Cardiovasc Surg 1968; 55:634–7.
[71] Zaheer S, Allen MS, Cassivi SD, Nichols FC III, Johnson CH, Deschamps C
et al. Postpneumonectomy empyema: results after the Clagett procedure.
Ann Thorac Surg 2006;82:279–86; discussion 286–277.
[72] Massera F, Robustellini M, Pona CD, Rossi G, Rizzi A, Rocco G. Predictors
of successful closure of open window thoracostomy for postpneumonect-
omy empyema. Ann Thorac Surg 2006;82:288–92.
[73] Gossot D, Stern JB, Galetta D, Debrosse D, Girard P, Caliandro R et al.
Thoracoscopic management of postpneumonectomy empyema. Ann
Thorac Surg 2004;78:273–6.
[74] Ng T, Ryder BA, Maziak DE, Shamji FM. Treatment of postpneumonect-
omy empyema with debridement followed by continuous antibiotic irri-
gation. J Am Coll Surg 2008;206:1178–83.
[75] Haghshenasskashani A, Rahnavardi M, Yan TD, McCaughan BC.
Intrathoracic application of a vacuum-assisted closure device in managing
pleural space infection after lung resection: is it an option? Interact
CardioVasc Thorac Surg 2011;13:168–74.
[76] Groetzner J, Holzer M, Stockhausen D, Tchashin I, Altmayer M, Graba M
et al. Intrathoracic application of vacuum wound therapy following thor-
acic surgery. Thorac Cardiovasc Surg 2009;57:417–20.
[77] Saadi A, Perentes JY, Gonzalez M, Tempia-Caliera A, Demartines N, Ris HB
et al. The intrathoracic vacuum assisted closure (VAC) device as tool to
control thoracic sepsis. In: 17th European Conference on General Thoracic
Surgery 2009, p. S27. European Association for Cardio-Thoracic Surgery,
Krakow, Poland.
[78] Gharagozloo F, Trachiotis G, Wolfe A, DuBree KJ, Cox JL. Pleural space
irrigation and modiﬁed Clagett procedure for the treatment of early post-
pneumonectomy empyema. J Thorac Cardiovasc Surg 1998;116:943–8.
[79] Wong PS, Goldstraw P. Post-pneumonectomy empyema. Eur J Cardiothorac
Surg 1994;8:345–9; discussion 349–350.
[80] Jadczuk E. Posptneumonectomy empyema. Eur J Cardiothorac Surg 1998;
14:123–6.
[81] Kacprzak G, Marciniak M, Addae-Boateng E, Kolodziej J, Pawelczyk K.
Causes and management of postpneumonectomy empyemas: our experi-
ence. Eur J Cardiothorac Surg 2004;26:498–502.
European Journal of Cardio-Thoracic Surgery 48 (2015) 653–654 EDITORIAL COMMENT
doi:10.1093/ejcts/ezv290 Advance Access publication 7 September 2015
Cite this article as: Mathisen DJ. Searching for answers!. Eur J Cardiothorac Surg 2015;48:653–4.
Searching for answers!
Douglas J. Mathisen*
Department of Thoracic Surgery, Massachusetts General Hospital, Boston, MA, USA
* Corresponding author. Department of Thoracic Surgery, Massachusetts General Hospital, 55 Fruit Street, Blake 1570, Boston, MA 02114, USA.
Tel: +1-617-7266826; fax: +1-617-7267667; e-mail: dmathisen@partners.org (D.J. Mathisen).
Keywords: Empyema • Pleural infection • Lung
This is an editorial comment on the EACTS expert consensus state-
ment for surgical management of pleural empyema, published in
this issue of the journal [1].
Empyema is a major problem worldwide. It presents in devel-
oped and undeveloped countries alike, countries with unlimited
resources and countries with minimal resources to manage this
problem, respectively. Doctors today taking care of patients with
the spectrum of presentations of empyema need guidance regard-
ing therapeutic options and when they are appropriate. Ideally, ran-
domized prospective studies would answer many of the questions
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